Navigating the regulatory landscape and analytical purity standards of synthetic growth hormone-releasing hormone (GHRH) analogs requires precise differentiation between clinical approval status and certified laboratory reference materials. CJC-1295 Mono (Modified GRF 1-29) is an unapproved investigational research peptide available exclusively for in vitro and preclinical research applications. PX1 Research provides fully certified, high-purity research compounds backed by lot-specific analytical documentation for academic and institutional research settings.
Navigating the regulatory landscape and analytical purity standards of synthetic growth hormone-releasing hormone (GHRH) analogs requires precise differentiation between clinical approval status and certified laboratory reference materials. CJC-1295 Mono (Modified GRF 1-29) is an unapproved investigational research peptide available exclusively for in vitro and preclinical research applications. PX1 Research provides fully certified, high-purity research compounds backed by lot-specific analytical documentation for academic and institutional research settings.
CJC-1295 Mono (also known as Modified GRF 1-29 or CJC-1295 without DAC) is not approved by the United States Food and Drug Administration (FDA) for human clinical use, medical diagnosis, therapeutic treatment, or personal consumption. No synthetic CJC-1295 formulation holds an approved New Drug Application (NDA) or Biologics License Application (BLA) for clinical administration.
When listed as 'certified for sale,' CJC-1295 Mono refers strictly to analytical-grade reference material verified for chemical purity, identity, and sequence integrity for non-clinical laboratory research. Laboratory researchers looking to procure high-purity compounds can explore our complete catalog of research peptides for compliant, in vitro research applications.
It is essential for procurement officers and laboratory investigators to distinguish between pharmaceutical approval for clinical administration and analytical certification for laboratory experimentation. Certified research-grade CJC-1295 Mono is synthesized in compliance with quality management standards to ensure reproducibility in scientific models, but it remains strictly classified as a research chemical for in vitro and laboratory animal research.
CJC-1295 Mono is a synthetic 29-amino-acid peptide derivative corresponding to the functional N-terminal region of native human growth hormone-releasing hormone (GHRH 1-44). Specifically, it represents a tetrasubstituted modification of human GHRH (1-29), featuring specific amino acid substitutions at positions 2, 8, 15, and 27 (D-Ala2, Gln8, Ala15, and Leu27).
These strategic enzymatic modifications enhance resistence against rapid cleavage by dipeptidyl peptidase-4 (DPP-IV), a primary endopeptidase responsible for the degradation of endogenous GHRH in plasma. By substituting native L-alanine with D-alanine at position 2, the peptide bond resists enzymatic hydrolysis, thereby increasing the half-life relative to native GHRH (1-29) while retaining full receptor binding selectivity.
Unlike its counterpart CJC-1295 DAC (Drug Affinity Complex), CJC-1295 Mono does not contain the maleimidopropionic acid linker. Consequently, it does not covalently bind to circulating serum albumin. This architectural distinction grants CJC-1295 Mono a distinct pharmacokinetic profile characterized by a shorter, pulsatile window of action suitable for studies requiring physiological simulation of natural somatotrope signaling. Researchers evaluating structural variations can inspect CJC-1295 Mono research material directly within our analytical database.
In vitro and animal model studies indicate that CJC-1295 Mono functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) located on anterior pituitary somatotropes. Receptor binding initiates a intracellular cascade mediated by heterotrimeric G-protein (Gs) coupling, activating adenylyl cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP) levels.
Preclinical data suggest that elevated cAMP triggers protein kinase A (PKA) signaling, opening voltage-gated calcium channels and causing the exocytosis of pre-synthesized growth hormone (GH) storage vesicles. Concurrently, this pathway stimulates transcription factors such as Pit-1, promoting the gene expression and synthesis of new growth hormone molecules.
Because CJC-1295 Mono retains a pulsatile secretion curve rather than continuous elevation, rodent models demonstrate that it induces episodic GH release without causing GHRH receptor desensitization or downregulation when administered within established experimental protocols. Downstream, sustained episodic GH release promotes hepatic transcription and systemic elevation of Insulin-like Growth Factor 1 (IGF-1), providing a controlled model for studying the somatotropic axis.
In preclinical settings, CJC-1295 Mono is widely studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. Researchers utilize this compound to evaluate extracellular matrix remodeling, collagen synthesis rates, and musculoskeletal cellular turnover following controlled mechanical injury models.
In vitro assays evaluating chondrocyte and osteoblast cell lines indicate that activation of the GHRH/IGF-1 axis by CJC-1295 Mono upregulates markers of cellular proliferation and collagen type I and III gene expression. These mechanisms are central to investigative models exploring articular cartilage preservation, tendon healing kinetics, and bone mineral density restoration.
Additionally, preclinical metabolic studies evaluate CJC-1295 Mono for its influence on adipocyte lipolysis and nitrogen retention. In rodent models of metabolic impairment, targeted GHRH receptor stimulation has been observed to enhance free fatty acid oxidation while sparing lean skeletal muscle mass during catabolic stress states. For broader background on secretagogue mechanisms, review our comprehensive PX1 Research knowledge base.
Understanding where CJC-1295 Mono fits within the broader landscape of somatotropic research compounds requires direct comparison with related GHRH analogs and growth hormone secretagogues (GHSR agonists). Each compound exhibits distinct half-life characteristics, receptor affinities, and secretory profiles in experimental models.
While CJC-1295 Mono provides a modified half-life (~30 minutes in rodent models) suitable for mimicking pulsatile GH release, CJC-1295 DAC incorporates a maleimide moiety that binds serum albumin, extending its biological half-life to several days and producing continuous baseline GH elevation. Conversely, basic native analogs such as Sermorelin retain the unsubstituted GHRH (1-29) structure, resulting in rapid enzymatic inactivation by DPP-IV and a drastically shorter biological duration.
Furthermore, researchers frequently contrast GHRH analogs with selective ghrelin receptor agonists like Ipamorelin. While CJC-1295 Mono targets the GHRHR directly, Ipamorelin acts via the growth hormone secretagogue receptor (GHSR-1a). Dual-pathway synergistic protocols in cell culture and animal models often evaluate co-stimulation of both GHRHR and GHSR-1a to observe maximal GH release without raising plasma cortisol or prolactin levels. For a deep dive into comparative dynamics, consult our analysis on CJC-1295 versus Sermorelin comparison.
Given the unapproved status of CJC-1295 Mono for human use, acquiring verified analytical-grade material is paramount for ensuring valid, reproducible experimental data. Commercial products supplied without rigorous chemical verification risk cross-contamination, variable peptide content, or presence of immunological triggers such as bacterial endotoxins.
PX1 Research enforces strict analytical protocol standards across every production batch. All compounds are USA-manufactured in GMP-compliant facilities and undergo independent evaluation by an ISO 17025 accredited laboratory. Primary testing methodologies include Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity (consistently exceeding 99%) and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify precise molecular weight and sequence identity.
Additionally, every lot undergoes chromogenic Limulus Amebocyte Lysate (LAL) testing to verify that bacterial endotoxin levels remain strictly below <0.5 EU/mg. Every shipment includes a lot-traceable, downloadable Certificate of Analysis (COA) detailing raw HPLC chromatograms and mass spectra data. Investigators managing large-scale facility requirements can access our portal for institutional wholesale accounts.
To preserve structural integrity and prevent chemical degradation, lyophilized CJC-1295 Mono must be handled according to standard laboratory peptide protocols. Upon receipt, lyophilized vials should be stored in a controlled freezer environment at -20°C or -80°C, protected from light and moisture exposure.
Reconstitution should be conducted within a certified laminar flow hood using sterile laboratory solvents such as bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl), depending on the requirements of the specific assay. The solvent should be directed down the glass wall of the vial rather than sprayed directly onto the peptide cake to avoid mechanical shear stress.
Following gentle swirl agitation (avoiding vortexing), reconstituted solutions should be aliquoted into single-use polypropylene microtubes to avoid repeated freeze-thaw cycles. Reconstituted aqueous CJC-1295 Mono should be stored at 2°C to 8°C and utilized within 14 to 21 days to minimize hydrolysis and peptide aggregation. Detailed handling guidelines across various analogs are detailed in our guide on secretagogue mechanisms.
Purchasing CJC-1295 Mono legally in the United States requires strictly operating within the boundaries of laboratory research compliance. Search queries regarding 'FDA approved certified for sale' reflect common confusion between pharmaceutical marketing terms and legal research material supply.
PX1 Research operates explicitly as a scientific supplier providing chemical standards for laboratory evaluation. CJC-1295 Mono is sold strictly as a non-clinical research chemical. Procurement agents and primary investigators must ensure that compounds purchased are utilized exclusively in controlled laboratory equipment, in vitro assays, or compliant preclinical animal models under appropriate institutional review board (IRB) or Institutional Animal Care and Use Committee (IACUC) oversight.
By maintaining uncompromising quality assurance, US-based manufacturing, ISO 17025 third-party validation, and rapid same-day dispatch from our California and Arizona fulfillment hubs, PX1 Research stands as the premier partner for institutional research requirements.
Is CJC-1295 Mono FDA approved for human therapeutic use?
No. CJC-1295 Mono is not FDA approved for clinical, medical, or therapeutic use in humans. It is an unapproved investigational compound certified strictly for non-clinical laboratory research.
What does 'certified for sale' mean for CJC-1295 Mono?
It indicates that the material has been analytically tested and certified for chemical identity, sequence accuracy, high purity (≥99%), and low endotoxin content by an accredited laboratory for sale to qualified research institutions.
What is the primary structural difference between CJC-1295 Mono and CJC-1295 DAC?
CJC-1295 Mono (Modified GRF 1-29) lacks the Drug Affinity Complex (DAC) lysine-linker moiety. As a result, it does not bind to serum albumin, resulting in a shorter, pulsatile pharmacokinetic profile compared to the extended half-life of CJC-1295 DAC.
How is CJC-1295 Mono purity verified at PX1 Research?
Every lot is verified using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity assessment and Mass Spectrometry (MS) for molecular weight confirmation in an independent ISO 17025 accredited laboratory.
What are the endotoxin limits for PX1 Research compounds?
All research peptides, including CJC-1295 Mono, undergo chromogenic LAL testing to ensure bacterial endotoxin levels remain below <0.5 EU/mg, preventing confounding inflammatory responses in cell culture and animal models.
How should lyophilized CJC-1295 Mono be stored upon arrival?
Lyophilized vials should be stored at -20°C or -80°C in a dry, dark environment. After reconstitution with an appropriate sterile solvent, solutions should be kept at 2°C to 8°C and used within two to three weeks.
Can CJC-1295 Mono be combined with Ipamorelin in preclinical research?
Yes. Preclinical literature frequently explores co-administration of GHRH analogs like CJC-1295 Mono with GHRP secretagogues like Ipamorelin to investigate synergistic growth hormone release pathways.
Where does PX1 Research manufacture and ship CJC-1295 Mono?
PX1 Research peptides are manufactured in US-based GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona with same-day dispatch for orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.